Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential

Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the tr...

Full description

Bibliographic Details
Main Authors: Fernandez C, van Halsema CL
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:HIV/AIDS: Research and Palliative Care
Subjects:
Online Access:https://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIV
_version_ 1818691844365615104
author Fernandez C
van Halsema CL
author_facet Fernandez C
van Halsema CL
author_sort Fernandez C
collection DOAJ
description Cristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors
first_indexed 2024-12-17T12:48:21Z
format Article
id doaj.art-a09d2af3a9054c7f880cb8e75d206c4b
institution Directory Open Access Journal
issn 1179-1373
language English
last_indexed 2024-12-17T12:48:21Z
publishDate 2019-07-01
publisher Dove Medical Press
record_format Article
series HIV/AIDS: Research and Palliative Care
spelling doaj.art-a09d2af3a9054c7f880cb8e75d206c4b2022-12-21T21:47:40ZengDove Medical PressHIV/AIDS: Research and Palliative Care1179-13732019-07-01Volume 1117919247555Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potentialFernandez Cvan Halsema CLCristina Fernandez,1 Clare L van Halsema1,21Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK; 2Faculty of Education, Liverpool School of Tropical Medicine, Liverpool, UKAbstract: Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. Adding to the increasing body of evidence for newer two-drug combinations, phase II and phase III trial data to date demonstrate cabotegravir and rilpivirine combination injectable therapy to be non-inferior to selected oral triple-therapy alternatives. Most importantly, this therapy is reported to be acceptable to individuals taking the 4-weekly or 8-weekly injections, despite frequent injection-site reactions. Key outstanding questions include management of missed or delayed dosing, drug interactions and management of virological failure, as well as the efficacy of cabotegravir and rilpivirine in all HIV-1 subtypes. We describe clinical evidence to date and efficacy and challenges in selected populations, including women; those with prior virological failure; individuals with a history of difficulty adhering to oral therapy and individuals with co-infections. We await real-world data and longer-term evidence while moving forward to this new era of antiretroviral therapy.Keywords: antiretroviral therapy, integrase inhibitors, non-nucleoside reverse transcriptase inhibitorshttps://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIVantiretroviral therapyintegrase inhibitorsnon-nucleoside reverse transcriptase inhibitors
spellingShingle Fernandez C
van Halsema CL
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
HIV/AIDS: Research and Palliative Care
antiretroviral therapy
integrase inhibitors
non-nucleoside reverse transcriptase inhibitors
title Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_full Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_fullStr Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_full_unstemmed Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_short Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
title_sort evaluating cabotegravir rilpivirine long acting injectable in the treatment of hiv infection emerging data and therapeutic potential
topic antiretroviral therapy
integrase inhibitors
non-nucleoside reverse transcriptase inhibitors
url https://www.dovepress.com/evaluating-cabotegravirrilpivirine-long-acting-injectable-in-the-treat-peer-reviewed-article-HIV
work_keys_str_mv AT fernandezc evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential
AT vanhalsemacl evaluatingcabotegravirrilpivirinelongactinginjectableinthetreatmentofhivinfectionemergingdataandtherapeuticpotential